Healthcare >> CEO Interviews >> October 26, 2004
ROGER G. STOLL has served as a Director of Cortex Pharmaceuticals, Inc.,
since April 2002 and became Chairman, President and Chief Executive
Officer of the company in August 2002. Dr. Stoll has extensive
experience in general management, research and development,
manufacturing, business development and strategic planning in the
pharmaceutical and medical products industry. Prior to joining Cortex,
Dr. Stoll worked as a consultant for several East Coast venture capital
firms and also consulted for various startup biomedical ventures. Dr.
Stoll's career includes senior management positions with Fresenius
Medical Care-North America, Ohmeda (BOC Group), Bayer AG, and American
Hospital Supply Corp. (now Baxter International). He started his
pharmaceutical career in 1972 at The Upjohn Company, where he conducted
human pharmacokinetic and metabolic studies. He obtained his BS in
Pharmacy from Ferris State University and a PhD in Biopharmaceutics from
the University of Connecticut. He also carried out post doctoral studies
in Pharmacokinetics at the University of Michigan under Dr. John Wagner. Profile
bring us up to date as to what has happened since we last spoke in
October of last year?
Dr. Stoll: Cortex is a
